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ENIGMA-MDD working group
ME Rentería1,2, L Schmaal3, DP Hibar4, B Couvy-Duchesne1,5,6, LT Strike5, NT Mills1,5, GI de Zubicaray7, KL McMahon6, SE Medland1,
NA Gillespie8, SN Hatton9, J Lagopoulos9, DJ Veltman3, N van der Wee10,11, TGM van Erp12, K Wittfeld13, HJ Grabe13,14, A Block15,
K Hegenscheid16, H Völzke17, IM Veer18, H Walter18, K Schnell19, E Schramm20,21, C Normann20, D Schoepf22, C Konrad23,24,
B Zurowski25, BR Godlewska26, PJ Cowen26, BWJH Penninx3, N Jahanshad4, PM Thompson4, MJ Wright5,6, NG Martin1,
H Christensen27 and IB Hickie9 for the ENIGMA-Major Depressive Disorder Working Group28
The aetiology of suicidal behaviour is complex, and knowledge about its neurobiological mechanisms is limited. Neuroimaging
methods provide a noninvasive approach to explore the neural correlates of suicide vulnerability in vivo. The ENIGMA-MDD
Working Group is an international collaboration evaluating neuroimaging and clinical data from thousands of individuals collected
by research groups from around the world. Here we present analyses in a subset sample (n= 3097) for whom suicidality data were
available. Prevalence of suicidal symptoms among major depressive disorder (MDD) cases ranged between 29 and 69% across
cohorts. We compared mean subcortical grey matter volumes, lateral ventricle volumes and total intracranial volume (ICV) in MDD
patients with suicidal symptoms (N= 451) vs healthy controls (N= 1996) or MDD patients with no suicidal symptoms (N= 650). MDD
patients reporting suicidal plans or attempts showed a smaller ICV (P= 4.12 × 10− 3) or a 2.87% smaller volume compared with
controls (Cohen’s d=− 0.284). In addition, we observed a nonsignificant trend in which MDD cases with suicidal symptoms had
smaller subcortical volumes and larger ventricular volumes compared with controls. Finally, no significant differences (P= 0.28–0.97)
were found between MDD patients with and those without suicidal symptoms for any of the brain volume measures. This is by far
the largest neuroimaging meta-analysis of suicidal behaviour in MDD to date. Our results did not replicate previous reports of
association between subcortical brain structure and suicidality and highlight the need for collecting better-powered imaging
samples and using improved suicidality assessment instruments.
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INTRODUCTION
Suicide has become a major public health issue for societies
around the world. According to the World Health Organisation,
more than 800 000 people die from suicide each year,1 and for
every completed suicide, there are between 10 and 20 attempted
suicides.2–4 It is also of concern that reported population rates
have increased by almost 60% between the 1960s and 2012, with
the largest increases seen in developing countries.3
The aetiology of suicidal behaviour is complex, and our
knowledge about its neurobiological mechanisms is limited.5
The stress vulnerability model for suicidal behaviour5 suggests
that a combination of individual genetic vulnerability and
exposure to environmental stressors is what triggers suicidal
behaviour. The current state of knowledge indicates that up to
38-55% of risk variance may be explained by genetic factors.6
Other known risk factors for suicidal behaviour include drug
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misuse, mood state and a range of cultural, family and social
situations. However, the main contributing vulnerability for
suicidal behaviour is having a history of self-harm and suicide
attempts or having a psychiatric disorder.7,8 In fact, up to 90% of
suicide victims may have a (often untreated) psychiatric
disorder,8,9 with major depressive disorder (MDD) affecting
between 50 and 70% of all victims.9–14
Typically, depressive episodes involve symptoms such as
hopelessness, negative affect and recurrent thoughts about death
and suicide.15 Twin, family and adoption studies have demon-
strated a significant genetic overlap between suicidal ideation and
depression,16 while also recognizing that a proportion of the
heritable component of suicidal behaviour is independent from
other psychiatric disorders.17,18 Remarkably, this is now reflected
in the newest version of the Diagnostic and Statistical Manual of
Mental Disorders (DSM-V),15 which has introduced suicidal
behaviour disorder as a diagnosis on its own, as compared with
previous versions in which it was only considered as a symptom of
a range of disorders. In addition, stressful life events (abuse/
assault, interpersonal conflict or loss, or employment difficulties)
also increase the likelihoods for both depression and suicidal
behaviour.19,20 Yet, despite multiple shared genetic and environ-
mental risk contributors, only a small proportion of individuals
with MDD who are confronted with acute stressors will display any
suicidal symptoms.
Although suicide is a preventable cause of death, predicting
and preventing suicidal behaviour has proven to be challenging.
At present, individual suicidality risk is assessed on the basis of
social, demographic and clinical factors, which despite being
highly sensitive, have low specificity.21 Several suicide-risk
questionnaires and scales have been proposed, achieving varying
degrees of predictive accuracy.22 One important consideration
is that it is sometimes difficult to obtain sufficient information
from patients who may not always be willing or able to share
subjective experiences with clinicians. Thus, the field has started
to focus on the underlying neuropsychological and neurobiolo-
gical mechanisms of suicidal behaviour. Ultimately, an improved
understanding of the neurobiology of suicidal vulnerability may
facilitate the development of more effective suicide-prevention
strategies.23
Magnetic resonance imaging of the brain provides a non-
invasive method by which to explore the neural correlates of
suicidal behaviour in vivo. Early structural magnetic resonance
imaging studies of suicidal behaviour in MDD showed promising
results, revealing smaller grey matter volumes of the orbitofrontal
cortex and larger amygdala volume in suicidal patients compared
with controls and nonsuicidal patients.24 Several literature reviews
of neuroimaging and suicidal behaviour have been published
recently.23,25–27 Studies in the literature suggest potential asso-
ciations between suicidality and brain regions such as the
orbitofrontal and anterior cingulate cortex.26,28 However, such
neuroanatomical patterns might not be consistent across indivi-
duals that display suicidal behaviour but suffer from different
psychiatric disorders.29,30 A possible explanation could be that
different pathways can lead to increased suicide vulnerability in
different psychiatric disorders, or that different components of
suicidal behaviour such as impulsivity, hopelessness, cognitive
rigidity or ideation are managed through different brain regions.
Empirical evidence indicates that suicidal behaviour is dissimilar in
patients with different psychiatric disorders.31 However, no formal
comparison has been conducted to date.
Together with the anterior cingulate cortex and orbitofrontal
cortex, subcortical regions of the striatum may be particularly
relevant for suicidal behaviour vulnerability in a depressed state as
compared with other states.26 Some MDD studies have reported
increases in amygdala volume24 or reductions in caudate and
pallidum volume in patients with a history of suicide attempts.32
However, as pointed out by others,26,33 published studies in the
field are few, and rely upon small sample sizes, which means
limited statistical power and higher risk of false positive/negative
associations. To overcome these limitations, increasing statistical
power and reliability, and advancing our understanding of the
neural correlates of suicidal vulnerability in MDD, we initiated a
project within the Major Depression Working Group of the
ENIGMA consortium,34 an international collaboration evaluating
neuroimaging and clinical data from a growing number of
research samples from around the world. Our aim is to identify
neuroimaging markers that robustly discriminate MDD patients
from healthy controls, using individual participant data-based
meta-analysis and incorporating standardized image processing
and statistical analysis protocols.
Previously, we performed a meta-analysis of subcortical
volumes35 and confirmed a reduction in hippocampal volume in
recurrent MDD patients relative to controls.35 Here we present a
series of analyses in a subset of that sample for which suicidality
data were available. We compare mean grey matter volumes of
seven subcortical structures, lateral ventricle volumes and total ICV
in MDD patients with suicidal symptoms vs either healthy controls
or MDD patients with no suicidal symptoms. Based on reports
from previous studies, we hypothesized that volumetric differ-
ences would be observed between suicidal and nonsuicidal
groups. This is by far the largest neuroimaging meta-analysis of
suicidal behaviour in MDD to date, and establishes a new platform
within the ENIGMA consortium for open collaboration among




At the time of data freeze for this study, the ENIGMA-MDD working group
included 20 samples with both neuroimaging and clinical data from
healthy controls and individuals who meet criteria for major depressive
disorder.35 A subset of seven of these cohorts were included in this
secondary project. Detailed demographics for each contributing site are
listed in Table 1. Diagnostic instruments used to determine MDD status,
specific items on suicidality and exclusion criteria for enrolment in each
sample are given in Supplementary Tables 1 and 2. In total, we analysed
data from 3097 participants including 1101 cases with MDD (451 of whom
exhibited suicidal ideation or behaviour) and 1996 healthy controls. All
participating sites obtained approval from local institutional review boards
and ethics committees, and all study participants provided written,
informed consent at their local institution.
Image processing and analysis
Structural T1-weighted magnetic resonance imaging brain scans were
acquired at each site and analysed locally using the fully automated and
validated segmentation software FreeSurfer36 (freely available at http://
surfer.nmr.mgh.harvard.edu/). Image acquisition parameters and software
descriptions for each sample are given in Supplementary Table 3. The
segmentations of seven subcortical grey matter regions (nucleus
accumbens, amygdala, caudate nucleus, hippocampus, pallidum, putamen,
thalamus), the lateral ventricles and total ICV were visually inspected for
accuracy following standardized protocols designed to facilitate harmo-
nized image analysis across multiple sites (http://enigma.ini.usc.edu/
protocols/imaging-protocols/). Segmentations deemed improper were
excluded from the analysis. Histogram plots were generated for each
region to examine the distribution of each volumetric variable. Outlier
measures (defined as 42.698 standard deviations away from the mean)
were all visually verified for accuracy, and excluded only if they were not
properly segmented.
Suicide nomenclature
Suicide, the act of intentionally terminating one’s life, is commonly
regarded as the extreme of a continuum, which also includes suicidal
ideation, planning and attempt.37 In this study, we were interested in
exploring the subcortical neuroanatomical correlates of the following
nonfatal suicidal manifestations in MDD: suicidal ideation, defined as
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thinking about suicide or taking one’s life, but without making any specific
plan or acting upon those thoughts; suicidal planning, or the systematic
formulation of a programme of action that has the potential to lead to a
suicide attempt. And, finally, a suicidal attempt, defined as any self-
initiated action aimed at terminating one’s life, regardless of the method or
degree of its consequences.
Considering that the number of suicidal attempters in the studies
included in this meta-analysis was too small to allow for any cross-group
comparison, it was decided to group the MDD cases with suicide attempt
with those MDD cases with suicide planning into a common category
called suicidal behaviour. Similarly, a broader category called suicidal
symptoms was created to include all MDD cases with any type of suicidal
symptom (that is, ideation or behaviour). It was not possible to ascertain
intent to die due to lack of information. See Supplementary Table 2 for a
description of how these different definitions of suicide were measured in
each individual site.
Meta-analyses
Within-group differences for MDD patients with or without suicidal
symptoms and healthy controls were analysed for each sample using
multiple linear regression models with total ICV or mean bilateral volume
[(volume of left hemisphere+volume of right hemisphere)/2] for each
region of interest as outcome measures and a binary indicator of status as
a predictor of interest.
The following groups were defined: healthy controls (CTL), MDD
cases with suicidal ideation (MDD-SI), MDD cases with suicidal behaviour
(that is, planning or attempt; MDD-SB), MDD cases with any suicidal
symptoms (that is, ideation, planning or attempt; MDD-SS) and MDD
cases with no suicidal symptoms (MDD-NSS). Four sets of cross-group
analyses were conducted, three of which were aimed at detecting
differences between MDD groups with suicidality and healthy controls,
and one more aimed at detecting differences in MDD patients with
suicidal symptoms vs those without: (i) MDD-SI (1) vs CTL (0); (ii)
MDD-SB (1) vs CTL (0); (iii) MDD-SS (1) vs CTL (0); and (iv) MDD-SS (1) vs
MDD-NSS (0). All models controlled for age, sex and, if applicable, total
ICV effects. Additional covariates were included whenever necessary to
control for scanner differences. We chose to perform these cross-group
comparisons for three reasons. First, considering the unprecedented
large sample size and that the number of studies in the literature
investigating ideation is limited,38 this was an exceptional opportunity to
investigate any potential correlates. Second, the degree of overlap
between the mechanisms that lead to ideation and those that activate and
control behaviour is not well established. We hoped that by analysing these
groups both independently and together, we could potentially gain insights
about their overlap. And third, any potential biomarker for suicidality in MDD
should ideally enable us to differentiate between MDD-SS and MDD-NSS,
rather than just between MDD-SS and CTL.
Effect size estimates were calculated using Cohen’s d metric computed
from the t-statistic of the status indicator variable from the regression
models. Uncorrected P-values are reported in this manuscript. To estimate
P-value thresholds that account for multiple testing, we performed matrix
spectral decomposition39 on a correlation matrix of the nine phenotypic
variables (ICV-adjusted mean subcortical and ventricular volumes, and ICV)
obtained from a sample of unrelated individuals from the QTIM sample
(N= 467). Given that common variance related to ICV had been removed,
the effective number of independent variables was 8.532. Thus, the P-value
threshold required to keep Type I error rate at 5% adjusted for the number
of independent variables being tested was 5.86 × 10− 3. Furthermore, after
considering the four types of cross-group comparisons that were
conducted, the required significance threshold at the meta-analysis level
was Po1.46 × 10− 3.
Finally, we performed an additional set of analyses to investigate any
potential influence of antidepressant (AD) use on our results. The only
information recorded consistently across studies was whether participants
were on AD treatment at the time of scanning (the proportion of
MDD patients on AD treatment in each sample is shown in Table 1).
Details about previous AD use history, duration, type or dosage of
treatment were not recorded and therefore the analyses only considered
AD use (yes/no) at the time of scanning, which was incorporated as a
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RESULTS
Prevalence of suicidal behaviour
The prevalence of suicidal symptoms among all MDD cases was
40% (451 individuals). Within-cohort prevalence among MDD
cases ranged between 29 and 69%. Of those reporting any suicidal
symptom, a total of 153 participants reported having at least
planned to take their life, and only 14 of them having actually
attempted to take their lives. Given the small number of participants
who had attempted suicide, it was decided to group together those
individuals who reported either having made a suicide plan or an
attempt in a group labelled as MDD with suicidal behaviour (MDD-
SB; see the 'Materials and methods' section for details).
Group differences in subcortical volumes
MDD suicidal ideation vs healthy controls. We meta-analysed and
compared differences across subcortical, ventricular and intracra-
nial volumes in MDD patients with suicidal ideation (N= 298) vs
healthy controls (N= 1996; Table 2). Adjusted Cohen’s d values
suggested small reductions in subcortical and intracranial volumes
and a slight increase in ventricular volume. No measure displayed
Table 2. Meta-analysis results for ventricular, subcortical and intracranial volumes, comparing MDD-SI vs healthy CTL
Brain volume Cohen's d
(CTL vs MDD-SI)
Std. err. 95% CI % Difference P-value Heterogeneity
(i2)
# CTL # MDD-SI
Lateral ventricles 0.119 0.071 [− 0.020, 0.257] 1.68 0.09 0.00 1910 292
Thalamus − 0.063 0.071 [− 0.202, 0.075] − 0.90 0.37 0.00 1892 293
Caudate − 0.011 0.074 [− 0.156, 0.133] − 0.15 0.88 7.40 1879 294
Putamen − 0.026 0.100 [− 0.222, 0.170] − 0.26 0.79 46.36 1825 289
Pallidum − 0.069 0.072 [− 0.209, 0.071] − 0.97 0.33 0.00 1861 288
Hippocampus − 0.052 0.087 [− 0.222, 0.118] − 0.60 0.55 30.81 1882 293
Amygdala − 0.106 0.071 [− 0.244, 0.033] − 1.49 0.14 0.00 1894 292
Accumbens 0.022 0.073 [− 0.121, 0.166] 0.30 0.76 3.91 1786 287
ICV − 0.028 0.096 [− 0.217, 0.160] − 0.29 0.77 44.16 1996 298
Abbreviations: CI, confidence interval; CTL, controls; ICV, intracranial volume; MDD, major depressive disorder; MDD-SI, MDD patients with suicidal ideation;
std. err., standard error. Age, sex, scan centre and ICV were used as covariates. Adjusted Cohen's d are reported. Samples included: all seven samples were
included. Samples excluded: none. Significance threshold: Po0.00146; i2 indicates heterogeneity across studies.
Table 3. Meta-analysis results for ventricular, subcortical and intracranial volumes, comparing MDD-SB vs healthy CTL
Brain volume Cohen's d
(CTL vs MDD-SB)
Std. err. 95% CI % Difference P-value Heterogeneity
(i2)
# CTL # MDD-SB
Lateral ventricles 0.022 0.093 [− 0.159, 0.204] 0.24 0.80 0.00 1713 103
Thalamus − 0.252 0.093 [− 0.434, − 0.69] − 2.70 0.007 0.00 1695 102
Caudate − 0.223 0.132 [− 0.481, 0.036] − 1.69 0.09 45.39 1682 107
Putamen − 0.155 0.094 [− 0.338, 0.029] − 1.65 0.10 0.00 1628 100
Pallidum − 0.027 0.093 [− 0.210, 0.156] − 0.29 0.78 0.00 1661 101
Hippocampus − 0.164 0.091 [− 0.343, 0.015] − 1.79 0.07 0.00 1685 107
Amygdala − 0.095 0.091 [− 0.273, 0.084] − 1.04 0.30 0.00 1697 107
Accumbens − 0.206 0.093 [− 0.388, − 0.023] − 2.21 0.03 0.00 1589 102
ICV − 0.071 0.199 [− 0.461, 0.320] − 0.35 0.72 76.69 1799 111
Abbreviations: CI, confidence interval; CTL, controls; ICV, intracranial volume; MDD, major depressive disorder; MDD-SB, MDD patients with suicidal planning/
attempt; std. err., standard error. Age, sex, scan centre and ICV were used as covariates. Adjusted Cohen's d are reported. Samples included: NESDA, SHIP, SHIP-
Trend, Sydney, QTIM. Samples excluded: DepOx and CODE. Significance threshold: Po0.00146; i2 indicates heterogeneity across studies.
Table 4. Meta-analysis results for ventricular, subcortical and intracranial volumes, comparing MDD-SS vs healthy CTL
Brain volume Cohen's d
(CTL vs MDD-SS)
Std. err. 95% CI % Difference P-value Heterogeneity (i2) # CTL # MDD-SS
Lateral ventricles 0.084 0.059 [− 0.032, 0.201] 1.41 0.16 0.00 1910 441
Thalamus − 0.121 0.060 [− 0.238, − 0.005] − 2.04 0.04 0.00 1892 443
Caudate − 0.077 0.082 [− 0.237, 0.084] − 0.94 0.35 42.59 1879 445
Putamen − 0.065 0.067 [− 0.197, 0.067] − 0.97 0.33 16.36 1825 435
Pallidum − 0.061 0.060 [− 0.179, 0.056] − 1.02 0.31 0.00 1861 433
Hippocampus − 0.085 0.075 [− 0.232, 0.062] − 1.14 0.26 32.89 1882 443
Amygdala − 0.101 0.059 [− 0.217, 0.015] − 1.71 0.89 0.00 1894 441
Accumbens − 0.056 0.060 [− 0.173, 0.062] − 0.93 0.35 0.00 1786 425
ICV − 0.058 0.106 [− 0.266, 0.150] − 0.55 0.59 66.57 1996 453
Abbreviations: CI, confidence interval; CTL, controls; ICV, intracranial volume; MDD, major depressive disorder; MDD-SS, MDD patients with suicidal ideation/
planning/attempt; std. err., standard error. Age, sex, scan centre and ICV were used as covariates. Adjusted Cohen's d are reported. Samples included: all seven
samples were included. Samples excluded: none. Significance threshold: Po0.00146; i2 indicates heterogeneity across studies.
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statistically significant differences between MDD-SI and CTL
groups at the study significance threshold (Po0.00146).
MDD suicidal behaviour (planning/attempt) vs healthy controls.
We meta-analysed and compared differences across subcortical,
ventricular and intracranial volumes in five cohorts (the CODE and
DepOx samples were excluded from the meta-analysis due to the
low number of MDD patients reporting suicide planning/attempt:
3 and 0, respectively). We compared brain volumes in MDD
patients with suicidal behaviour (planning/attempt, N= 150) vs the
healthy controls (N= 1893; Table 3). A similar trend was observed,
with reductions in intracranial and subcortical volumes and an
increase in ventricular volume. In fact, an ICV reduction in MDD
patients who reported having made suicidal plans or attempts
was nearly significant at the study-wide level (P= 4.12 × 10− 3),
with a Cohen’s d=− 0.284, or a 2.87% smaller ICV compared to the
CTL group.
MDD suicidal symptoms (ideation/planning/attempt) vs healthy
controls. Given that similar trends were observed in both MDD-
SI vs CTL and MDD-SB vs CTL analyses, we grouped together the
MDD-SI and MDD-SB groups, into a group we labelled as MDD
with suicidal symptoms (MDD-SS; N= 451), and compared them vs
healthy controls (N= 1996; Table 4). We consistently observed
reductions across subcortical and intracranial volumes and an
increase in ventricular volume in MDD-SS individuals. Thalamic
volume showed nominal significance (P= 0.041), and the amyg-
dala showed a nonsignificant trend (P= 0.087), but these P-values
did not survive correction for multiple testing.
To further investigate whether the pattern we observed
consistently in MDD patients with suicidal symptoms vs healthy
controls was due to structural brain differences linked to
suicidality rather than just MDD, we compared MDD-NSS vs CTL.
Although we did not observe a consistent pattern between MDD-
NSS and CTLs in this study (results shown in Supplementary Table
5), the pattern is in fact consistent with our previous MDD meta-
analysis, which did not separate individuals by suicidality.
MDD suicidal symptoms (ideation/planning/attempt) vs MDD with
no suicidal symptoms. Last, we compared subcortical, ventricular
and intracranial volumes in MDD-SS (N= 451), vs MDD cases
reporting no suicidal symptoms (MDD-NSS; N= 650; Table 5). The
largest difference was observed in the amygdala (Cohen’s d=0.081),
equivalent to a 1.09% difference in volume. However, this was not
significant (P=0.28), which indicates that it is not possible to
reject the null hypotheses, which states that mean volumes between
MDD-SS and MDD-NSS are not significantly different.
Antidepressant effects
To investigate the effects of AD use, we performed an additional
set of analyses including AD use (yes/no) at the time of scanning
as a covariate. The results are shown in Supplementary Table 4.
Although the AD-adjusted results suggest a possible significant
difference in thalamus volume between MDD-SS and healthy
controls, no significant difference was observed between MDD-SS
and MDD-NSS.
Power analysis
With 1910 healthy controls and 292 MDD-SI cases, we could detect
lateral ventricle volume differences as small as Cohen’s d= 0.119
(95% confidence interval =− 0.020, 0.258) for mean lateral
ventricles at a P= 0.09 significance level. A post hoc analysis
estimated the observed (two-tailed hypothesis) power of this
analysis at 0.347 at a study-wide significance threshold of
P= 0.001465, and a power of 0.796 at the nominal significance
threshold of P=0.05. Also, an a priori sample size calculation
indicated that to achieve a power of 0.8 to detect a Cohen’s
d=0.119 at P=0.001465, the study would need a minimum sample
of 2290 individuals per group in a two-tailed hypothesis analysis.
Similarly, based on the final meta-analysed effect sizes found in
our comparison between MDD-SS vs healthy controls, we could
detect a Cohen’s d=−0.121 (95% confidence interval =−0.238,
−0.005) at P=0.042, with 443 MDD-SS cases and 1892 healthy
controls. The observed (two-tailed hypothesis) power was estimated
at 0.396 at the study-wide significance threshold (P=0.001465), and
at 0.831 for nominal significance (P=0.05). To achieve a 0.8 power at
study-wide significance, 2215 individuals per group would be
needed. Last, considering that the largest difference between MDD-
SS and MDD-NSS was a Cohen’s d=0.081, we estimate that a
sample consisting of 2394 individuals per group would be needed
to achieve 0.8 power to detect a significant difference at P=0.05.
DISCUSSION
Although earlier studies suggested potential associations between
suicidality and subcortical brain regions such as the amygdala,24
caudate32,40 or pallidum,32 a recent study in a larger sample
(N= 274) of patients with mood disorder failed to replicate these
findings.33 To the best of our knowledge, we conducted the first
neuroimaging study that uses an international coordinated meta-
analytic approach to investigate potential neurobiological markers
for suicidality. We analysed individual participant neuroimaging
and clinical data of suicidal behaviour in MDD in the largest
sample to date (N= 3097), and participants encompassed diverse
Table 5. Meta-analysis results for ventricular, subcortical and intracranial volumes, comparing MDD-NSS vs MDD-SS
Brain volume Cohen's d
(MDD-NSS vs MDD-SS)
Std. Err. 95% CI % Difference P-value Heterogeneity (i2) # MDD-NSS # MDD-SS
Lateral ventricles 0.060 0.076 [− 0.900, 0.209] 0.78 0.43 0.00 626 441
Thalamus 0.021 0.076 [− 0.128, 0.171] 0.28 0.78 0.00 621 443
Caudate − 0.014 0.076 [− 0.163, 0.136] − 0.18 0.86 0.00 621 445
Putamen 0.036 0.111 [− 0.181, 0.253] 0.32 0.75 46.19 601 435
Pallidum − 0.056 0.088 [− 0.228, 0.116] − 0.64 0.52 18.21 604 433
Hippocampus 0.069 0.076 [− 0.081, 0.219] 0.91 0.36 0.00 629 443
Amygdala 0.065 0.076 [− 0.085, 0.214] 0.85 0.40 0.00 622 441
Accumbens 0.026 0.077 [− 0.125, 0.178] 0.34 0.73 0.00 593 425
ICV 0.064 0.077 [−0.088, 0.215] 0.83 0.41 0.00 643 453
Abbreviations: CI, confidence interval; ICV, intracranial volume; MDD, major depressive disorder; MDD-NSS, MDD patients with no suicidal ideation/planning/
attempt; MDD-SS, MDD patients with any suicidal symptom; std. err., standard error. Age, sex, scan centre and ICV were used as covariates. Adjusted Cohen's d
are reported. Samples included: all seven samples were included. Samples excluded: none. Significance threshold: Po0.00146; i2 indicates heterogeneity
across studies.
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degrees of disease severity, scanner acquisitions and geographies.
The meta-analytic approach achieves increased statistical power
by combining data from different sites using standardised image
processing, segmentation and data analysis protocols.
We analysed mean ventricular and subcortical grey matter
volumes and total ICV in MDD patients with and without suicidal
symptoms and healthy controls. Our results found no robust
association of suicidal behaviour with any of the nine neuroima-
ging traits under investigation at the study-wide significance
threshold (Po1.46 × 10− 3). Observed effect sizes were relatively
small, with the strongest effect observed for ICV between MD-SS
and healthy controls (2.83% difference in volume). Power analyses
indicated that given the observed Cohen’s d values, the current
study is underpowered and that considerably larger samples will
be needed (N= 4788 to achieve 0.8 power to detect a significant
mean difference at nominal threshold level P= 0.05). This suggests
that many of the previous reports of higher effect sizes in studies
with small sample sizes (even cohorts as small as 7,32 10 (ref. 24) or
15 (ref. 40) individuals) may be false positives, or due to very
specific characteristics of those samples. Therefore, we hope that
our results discourage positive outcome bias in the literature.
If the real effects of suicidality on subcortical brain volumes are
indeed small, an important question will be whether these effects
are clinically relevant. We believe that it is not possible to assess
the value of an effect based just on its effect size. Brain alterations
with a small effect size might still have clinical relevance if they are
associated with treatment response, prediction of clinical out-
comes or if they help identify novel disease mechanisms. Future
studies will need to confirm the relevance of these findings, and
more research is needed to uncover the neuroanatomical
correlates of suicidality.
Although not statistically significant, MDD-SI and MDD-SB patient
groups displayed smaller intracranial and subcortical volumes and
larger ventricular volumes compared with controls. These findings are
consistent with our results from our previous ENIGMA-MDD study35
on a larger sample, which did not take their suicidality symptoms into
account, and with the MDD-SS vs MDD-NSS analyses, where we
observed no significant differences (P=0.28–0.97). Therefore, we
cannot determine whether the observed pattern is associated with
suicidality or whether it is a part of the existing neuroanatomical
differences between MDD patients and healthy controls.
When controlling for AD use at the time of scanning, we
observed a significant difference in thalamic volume between MDD-
SS and healthy controls (P=0.006). However, this was not observed
between MDD-SS and MDD-NSS (P=0.841). One lesson from our
previous subcortical analyses of the larger ENIGMA-MDD working
group was that AD users tend to show more widespread structural
effects than non-antidepressant users.35 This might be because AD
users tend to be the most severe/chronic or recurrent patients in
the sample, and thus the results are likely to be confounded by
severity. In the present study, no data were available on medication
history, or duration, type and dosage of the treatment that patients
were receiving at the time of scanning, and therefore it is not
possible to reliably estimate the actual effects of antidepressants
with our current experimental design. This issue should be
investigated in future intervention studies that compare pre- and
post-AD treatment to draw conclusions on the impact of AD use on
suicidality and subcortical brain structure in MDD.
This study also presents some limitations. For instance, the
samples in the meta-analysis displayed low prevalence of suicidal
attempts and the effects of suicidality might not be detectable,
either because they are only noticeable in individuals who are at
very high risk or because the neural correlates of suicidality tend
to become acute only during certain periods of time and then
reduce quickly, unlike depression, which is less responsive. Also,
given the highly heterogeneous nature of both MDD and
suicidality, it is possible that there is more than one pathway that
increases suicide vulnerability and therefore it will be important to
gather more details about the frequency, severity or type of suicidal
thoughts and behaviour that patients experience. Further, while the
suicidality items used by contributing sites are routinely used to
assess suicidality symptoms in major depression, future studies
should consider the use of more robust and comprehensive
suicidality assessment instruments that gather information on the
cognitive, behavioural and affective processes of suicidality, such as
rumination, impulsivity or negative affect.41
In addition, despite our quality control, standardization and
harmonization efforts, which required significant work by all contri-
buting sites, we recognize that the studies in this meta-analysis do
still display methodological differences across sites. The criteria,
scanners, acquisition parameters and suicidality assessment instru-
ments were not strictly the same across groups. To test whether
methodological differences explained a significant proportion of the
variance in effect sizes across sites in the meta-analyses, we
performed a series of meta-regressions, where each moderator
variable (scanner field strength, voxel-size, FreeSurfer version used for
image processing, temporality of the suicidality item and percentage
of patients acutely depressed at the time of scanning) was separately
included as a fixed-effect predictor in the model. The significance
threshold for each moderator hypothesis was determined by false
discovery rate procedure at q=0.05. Our results (shown in
Supplementary Tables 6–11) showed that sample characteristics did
not significantly moderate effect size estimates of brain volumes in
any of the cross-group comparisons undertaken in this study.
Nonetheless, our results should be confirmed in future large scale
studies with improved and harmonized assessment of suicidality.
Given the considerable human and societal costs of suicide and
suicidal behaviour, many countries have developed suicide-
prevention programmes in recent years. However, the field faces
several major challenges and there is an urgent need for
biomarkers to aid in the prediction and prevention of suicidal
behaviour. Neuroimaging methods provide a great opportunity to
understand the structural and functional differences in the brains
of individuals with psychiatric disorders and suicidal symptoms.
However, as demonstrated here, major efforts might be needed to
discover such biomarkers.
Future efforts could focus around longitudinal studies, which can
provide insights about suicidality in the context of disease trajec-
tories, and scanning of subjects before and after drug treatment and
behavioural interventions to provide insights into disease mechan-
isms and treatment response. Finally, while this meta-analysis was
restricted to subcortical grey matter volumes, ventricular and
intracranial volumes, future studies should also try to replicate
previously reported associations of cortical phenotypes with
suicidality. In fact, future efforts within the ENIGMA-MDD working
group will include coordinating a large meta-analysis of cortical
phenotypes to identify potential biomarkers for suicidality in MDD,
and we invite groups from around the world to join our efforts.
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